

WHAT IS CLAIMED IS:

1 A method for identifying a compound that modulates angiogenesis,
2 the method comprising the steps of:

3 (i) contacting the compound with a ILKAP polypeptide, the polypeptide
4 encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid
5 encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:2; and

6 (ii) determining the functional effect of the compound upon the ILKAP
7 polypeptide.

1 2. The method of claim 1, wherein the functional effect is determined
2 *in vitro*.

1 3. The method of claim 2, wherein the functional effect is a physical
2 effect.

1 4. The method of claim 2, wherein the functional effect is determined
2 by measuring ligand binding to the polypeptide.

1 5. The method of claim 2, wherein the functional effect is a chemical
2 effect.

1 6. The method of claim 5, wherein the functional effect is determined
2 by measuring phosphatase activity of the polypeptide.

1 7. The method of claim 1, wherein the polypeptide is expressed in a
2 eukaryotic host cell.

1 8. The method of claim 7, wherein the functional effect is a physical
2 effect.

1 9. The method of claim 8, wherein the functional effect is determined
2 by measuring ligand binding to the polypeptide.

1 10. The method of claim 1, wherein the functional effect is a chemical
2 or phenotypic effect.

00935124-032101
TOT230-12152660

1 11. The method of claim 11, wherein the polypeptide is expressed in a
2 eukaryotic host cell.

1 12. The method of claim 11, wherein the host cell is an endothelial
2 cell.

1 13. The method of claim 12, wherein the functional effect is
2 determined by measuring avb3 expression, haptotaxis, or phosphatase activity.

1 14. The method of claim 1, wherein modulation is inhibition of
2 angiogenesis.

1. 15. The method of claim 1, wherein the polypeptide is recombinant.

1 16. The method of claim 1, wherein the polypeptide comprises a
2 sequence of SEQ ID NO:2.

1 17. The method of claim 1, wherein the compound is an antibody.

1 18. The method of claim 1, wherein the compound is an antisense
2 molecule.

1 19. The method of claim 1, wherein the compound is a small organic
2 molecule.

1 20. A method of modulating angiogenesis in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 compound identified using the method of claim 1.

1 21. The method of claim 20, wherein the subject is a human.

1 22. The method of claim 20, wherein the compound is an antibody.

1 23. The method of claim 20, wherein the compound is an antisense
2 molecule.

1 24. The method of claim 20, wherein the compound is a small organic
2 molecule.

1 25. The method of claim 20, wherein the compound inhibits
2 angiogenesis.

1 26. A method of modulating angiogenesis in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 ILKAP polypeptide, the polypeptide encoded by a nucleic acid that hybridizes under
4 stringent conditions to a nucleic acid encoding a polypeptide comprising an amino acid
5 sequence of SEQ ID NO:2.

1 27. A method of modulating angiogenesis in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 nucleic acid encoding a ILKAP polypeptide, wherein the nucleic acid hybridizes under
4 stringent conditions to a nucleic acid encoding a polypeptide comprising an amino acid
5 sequence of SEQ ID NO:2.

09935424-082101
TOT230-712TSE660